68 related articles for article (PubMed ID: 23159358)
1. Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients.
Phabphal K; Geater A; Limapichart K; Sathirapanya P; Setthawatcharawanich S
Seizure; 2013 Mar; 22(2):103-8. PubMed ID: 23159358
[TBL] [Abstract][Full Text] [Related]
2. The association between CYP 2C9 polymorphism and bone health.
Phabphal K; Geater A; Limapichat K; Sathirapanya P; Setthawatcharawanich S; Leelawattana R
Seizure; 2013 Nov; 22(9):766-71. PubMed ID: 23849849
[TBL] [Abstract][Full Text] [Related]
3. The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy.
Twardowschy CA; Werneck LC; Scola RH; Borgio JG; De Paola L; Silvado C
Seizure; 2013 Apr; 22(3):194-7. PubMed ID: 23298603
[TBL] [Abstract][Full Text] [Related]
4. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.
Twardowschy CA; Werneck LC; Scola RH; De Paola L; Silvado CE
Arq Neuropsiquiatr; 2011 Apr; 69(2A):153-8. PubMed ID: 21537551
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients.
Ramasamy K; Narayan SK; Shewade DG; Chandrasekaran A
Ther Drug Monit; 2010 Dec; 32(6):762-6. PubMed ID: 21068649
[TBL] [Abstract][Full Text] [Related]
6. The association between BsmI polymorphism and bone mineral density in young patients with epilepsy who are taking phenytoin.
Phabphal K; Geater A; Limapichart K; Sathirapanya P; Setthawatcharawanich S; Witeerungrot N; Thammakumpee N; Leelawattana R
Epilepsia; 2013 Feb; 54(2):249-55. PubMed ID: 23281616
[TBL] [Abstract][Full Text] [Related]
7. The association between BsmI polymorphism and risk factors for atherosclerosis in patients with epilepsy taking valproate.
Phabphal K; Geater A
Seizure; 2013 Nov; 22(9):692-7. PubMed ID: 23755911
[TBL] [Abstract][Full Text] [Related]
8. Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals.
Kaur-Knudsen D; Bojesen SE; Nordestgaard BG
Pharmacogenomics J; 2009 Oct; 9(5):327-32. PubMed ID: 19652664
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.
Shintani M; Ieiri I; Inoue K; Mamiya K; Ninomiya H; Tashiro N; Higuchi S; Otsubo K
Clin Pharmacol Ther; 2001 Aug; 70(2):175-82. PubMed ID: 11503012
[TBL] [Abstract][Full Text] [Related]
10. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects.
Soga Y; Nishimura F; Ohtsuka Y; Araki H; Iwamoto Y; Naruishi H; Shiomi N; Kobayashi Y; Takashiba S; Shimizu K; Gomita Y; Oka E
Life Sci; 2004 Jan; 74(7):827-34. PubMed ID: 14659971
[TBL] [Abstract][Full Text] [Related]
11. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
[TBL] [Abstract][Full Text] [Related]
13. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients.
Thakkar AN; Bendkhale SR; Taur SR; Gogtay NJ; Thatte UM
Neurol India; 2012; 60(6):577-80. PubMed ID: 23287317
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.
Imai J; Ieiri I; Mamiya K; Miyahara S; Furuumi H; Nanba E; Yamane M; Fukumaki Y; Ninomiya H; Tashiro N; Otsubo K; Higuchi S
Pharmacogenetics; 2000 Feb; 10(1):85-9. PubMed ID: 10739176
[No Abstract] [Full Text] [Related]
15. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.
Tate SK; Depondt C; Sisodiya SM; Cavalleri GL; Schorge S; Soranzo N; Thom M; Sen A; Shorvon SD; Sander JW; Wood NW; Goldstein DB
Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5507-12. PubMed ID: 15805193
[TBL] [Abstract][Full Text] [Related]
16. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
Lee SY; Lee ST; Kim JW
J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions.
Lee AY; Kim MJ; Chey WY; Choi J; Kim BG
Eur J Clin Pharmacol; 2004 May; 60(3):155-9. PubMed ID: 15024534
[TBL] [Abstract][Full Text] [Related]
18. Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India.
Ramasamy K; Narayan SK; Chanolean S; Chandrasekaran A
Neurol India; 2007; 55(4):408-9. PubMed ID: 18040121
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics: reality or fiction? Or are we there yet?
Lopes-Cendes I; Guerreiro CA
Arq Neuropsiquiatr; 2011 Apr; 69(2A):151-2. PubMed ID: 21537550
[No Abstract] [Full Text] [Related]
20. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.
Kesavan R; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2010 Jul; 66(7):689-96. PubMed ID: 20390258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
